Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Vikram Deshpande, M.B.,B.S.

Co-Author

This page shows the publications co-authored by Vikram Deshpande and Keith Lillemoe.
Connection Strength

1.899
  1. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Histopathology. 2020 Jul; 77(1):35-45.
    View in: PubMed
    Score: 0.219
  2. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Mod Pathol. 2019 06; 32(6):844-854.
    View in: PubMed
    Score: 0.200
  3. Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg. 2016 05; 20(5):953-9.
    View in: PubMed
    Score: 0.163
  4. Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1604.
    View in: PubMed
    Score: 0.160
  5. Erratum to: The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1609.
    View in: PubMed
    Score: 0.160
  6. The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. Ann Surg Oncol. 2016 Jan; 23(1):290-6.
    View in: PubMed
    Score: 0.150
  7. Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2021 04 15; 27(8):2314-2325.
    View in: PubMed
    Score: 0.057
  8. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. J Natl Cancer Inst. 2021 02 01; 113(2):182-191.
    View in: PubMed
    Score: 0.057
  9. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg. 2021 11; 25(11):2859-2870.
    View in: PubMed
    Score: 0.057
  10. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Ann Surg Oncol. 2021 Aug; 28(8):4592-4601.
    View in: PubMed
    Score: 0.057
  11. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Ann Surg. 2020 Oct 19.
    View in: PubMed
    Score: 0.056
  12. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2020 08; 272(2):357-365.
    View in: PubMed
    Score: 0.055
  13. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
    View in: PubMed
    Score: 0.051
  14. Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). Clin Cancer Res. 2019 04 15; 25(8):2644-2655.
    View in: PubMed
    Score: 0.050
  15. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Ann Surg. 2019 Jan 18.
    View in: PubMed
    Score: 0.050
  16. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. J Gastrointest Surg. 2017 Nov; 21(11):1831-1840.
    View in: PubMed
    Score: 0.045
  17. Primary lymph node gastrinoma: A single institution experience. Surgery. 2017 11; 162(5):1088-1094.
    View in: PubMed
    Score: 0.045
  18. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5959-5969.
    View in: PubMed
    Score: 0.045
  19. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2016 12; 23(Suppl 5):609-617.
    View in: PubMed
    Score: 0.041
  20. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8.
    View in: PubMed
    Score: 0.040
  21. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7.
    View in: PubMed
    Score: 0.038
  22. Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. World J Gastrointest Surg. 2014 Jul 27; 6(7):136-41.
    View in: PubMed
    Score: 0.037
  23. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6.
    View in: PubMed
    Score: 0.033
  24. Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery. 2012 Sep; 152(3 Suppl 1):S43-9.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.